The ability of therapeutic cancer vaccines to induce antigen-specific T cell immune response against the tumor and the ability of ICIs to increase anti-tumor activity of CD8+ T cells led to the combination of these two therapeutic strategies [12,14,15,16,17]. Here, CD8A is linked to neoplasm.